Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
•There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to...
Gespeichert in:
Veröffentlicht in: | Transplantation and cellular therapy 2021-06, Vol.27 (6), p.483.e1-483.e6 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •There was a higher rate of treatment-related mortality with myeloablative conditioning, but this was offset by a much higher rate of relapse with reduced-intensity conditioning.•There was no difference in survival following relapse based on conditioning intensity.•Myeloablative conditioning led to improved overall survival in patients with myelodysplastic syndrome or acute myelogenous leukemia who underwent allogeneic transplantation.
Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with |
---|---|
ISSN: | 2666-6367 2666-6375 2666-6367 |
DOI: | 10.1016/j.jtct.2021.02.031 |